AddLife AB Reports 6% Revenue Increase and 30% Profit Growth in Q2 2026, Boosted by Strategic Acquisitions

AddLife Achieves SEK 2,721 Million in Q2 2026 Net Sales Through Organic and Acquisition Growth

In Q2 2026, AddLife reported net sales of SEK 2,721 million, up from SEK 2,578 million in the same quarter last year, reflecting a 6 percent headline increase. Adjusted for divested operations from December 2025, organic growth contributed 4 percent, and acquisitions added 3 percent to revenue in the quarter. This blend of organic and inorganic growth underscores AddLife's dual-track expansion strategy, leveraging both the operational strength of its subsidiaries and a consistent pipeline of bolt-on acquisitions across the European Life Science sector.

The revenue growth is notable amid a challenging macroeconomic environment where healthcare and life science sectors have faced diverse demand and cost pressures across Europe. Although the announcement does not detail subsidiary or country-level results, the group-wide figures suggest that the diversified network of around 85 businesses across multiple European markets has provided resilience. Regional revenue splits and product category contributions were not disclosed, but the overall outcome supports CEO Fredrik Dalborg's confidence in the group's operational momentum.

EBITA Margin Improves to 12.6% in Q2 2026 as Operational Enhancements Yield Results

EBITA rose 11 percent in Q2 to SEK 342 million from SEK 307 million a year earlier, with the EBITA margin expanding to 12.6 percent from 11.9 percent, a 70 basis point improvement year-on-year. This margin growth indicates that AddLife's operational improvement initiatives are delivering tangible financial benefits. Management highlighted that recently acquired companies are significantly contributing to earnings growth, demonstrating effective integration processes.

For the first half of 2026, EBITA increased 4 percent to SEK 674 million from SEK 650 million in H1 2025, despite a roughly 2 percent negative impact from currency fluctuations. The EBITA margin for H1 improved to 12.6 percent from 12.3 percent the previous year. While a specific currency-adjusted EBITA figure was not provided, the underlying performance trend appears positive when excluding exchange rate effects.

Profit After Tax Surges 30% in Q2 and 17% in H1 2026 at AddLife

Profit after tax jumped 30 percent to SEK 130 million in Q2 2026 from SEK 100 million in Q2 2025, marking a standout metric. The faster profit growth relative to revenue and EBITA suggests favorable movements in below-EBITA items such as financing costs, amortization, or taxes, though detailed breakdowns were not provided. Earnings per share for Q2 2026 rose to SEK 1.06 from SEK 0.83 the prior year, a significant improvement for investors assessing per-share value.

In H1 2026, profit after tax increased 17 percent to SEK 258 million from SEK 220 million, with earnings per share rising to SEK 2.11 from SEK 1.81. The latest 12-month EPS of SEK 4.89 nearly doubles the SEK 2.76 recorded in the previous 12-month period, a key indicator for investors evaluating long-term profitability and potential dividend or capital return prospects, though no distribution guidance was provided.

Operating Cash Flow Reaches SEK 165 Million in Q2 2026 Amid Solid Financial Position

Operating cash flow in Q2 2026 rose approximately 39 percent to SEK 165 million from SEK 119 million in Q2 2025. This improvement aligns with the group's focus on cash conversion alongside profitability, enabling continued acquisition activity without substantially increasing leverage. Management cited stronger margins, growth, and increased cash flow as positive traits of the current trading period.

However, H1 2026 operating cash flow declined to SEK 269 million from SEK 359 million in H1 2025, a decrease of about SEK 90 million. The announcement did not elaborate on this variance, and investors may seek further explanation during the scheduled video conference. The equity ratio remained steady at 43 percent year-on-year, while return on working capital (P/WC) was 61 percent compared to 62 percent previously, indicating consistent capital efficiency.

Acquisition of Austria's CoaChrom Diagnostica GmbH Adds SEK 110 Million Annual Sales

In Q2 2026, AddLife completed the acquisition of CoaChrom Diagnostica GmbH, an Austria-based company expected to contribute approximately SEK 110 million in annual net sales. This acquisition expands AddLife's footprint in Austria and aligns with its strategy to grow through targeted bolt-on acquisitions across Europe’s Life Science sector. Financial terms and specific product or service details were not disclosed.

This acquisition represents one of two completed in H1 2026, with combined annual net sales contributions estimated at SEK 185 million. The second acquisition, not individually named, is expected to add around SEK 75 million annually. AddLife’s acquisition strategy remains a core growth driver, with management confirming active pursuit of further deals. Investors will likely watch for announcements of additional transactions, as acquired growth continues to support overall performance.

CEO Fredrik Dalborg and CFO Christina Rubenhag to Present H1 2026 Results in Investor Video Conference

CEO Fredrik Dalborg and CFO Christina Rubenhag will present AddLife’s interim results during a video conference open to investors, analysts, and media. The English-language presentation, scheduled for 9 a.m. Central European Summer Time on 16 July 2026, will last about 20 minutes followed by a Q&A session. A recording will be available online afterward, and the presentation can be accessed via AddLife’s YouTube channel.

This format emphasizes AddLife’s commitment to transparent communication, offering the investment community a chance to inquire about financial details, currency impacts, cash flow variations, and acquisition pipelines. Contact details for Fredrik Dalborg and Christina Rubenhag were provided, and the full interim report for January to June 2026 is downloadable in PDF format at reports-en.add.life.

AddLife’s Network of 85 European Subsidiaries and SEK 10 Billion Rolling Revenue Support Growth

AddLife operates as an independent Life Science partner, supplying high-quality products, services, and advice to private and public sector clients across Europe. The group employs about 2,300 people within approximately 85 subsidiaries and generates rolling net sales exceeding SEK 10 billion. Its decentralized network of specialist businesses serves diverse healthcare and Life Science markets, combining local expertise with group-level resources and capital allocation.

The Life Science sector includes diagnostics, laboratory equipment, medical devices, and related consumables, where AddLife’s subsidiaries are active. The mix of public healthcare procurement and private sector demand offers revenue visibility and resilience. Listed on Nasdaq Stockholm, AddLife attracts Swedish and international investors and holds a significant position as a consolidator in the fragmented European Life Science distribution and services market.

Currency Effects and Divestitures Influence AddLife’s H1 2026 Growth Figures

Reported H1 2026 net sales grew 2 percent to SEK 5,366 million from SEK 5,280 million in H1 2025, influenced by two key factors. Currency fluctuations negatively impacted net sales by about 2 percent due to the group’s exposure to the euro and other European currencies against the Swedish krona. Additionally, divestitures completed in December 2025 mean prior period comparatives included now-divested operations.

Adjusting for divestitures and currency effects, organic growth in H1 2026 was 3 percent, with acquisitions adding 2 percent, resulting in an underlying constant-currency growth of approximately 5 percent. This distinction is important for investors comparing AddLife’s performance with peers or internal goals. Currency headwinds also reduced EBITA by about 2 percent in H1, indicating stronger underlying margin and earnings improvements than headline figures suggest.

Active Acquisition Pipeline Remains Central to AddLife’s Growth Strategy

AddLife’s interim report reiterates its commitment to acquisitive growth. CEO Fredrik Dalborg emphasized the group’s active pursuit of further acquisitions, continuing a strategy that has driven expansion across Europe. The two acquisitions completed in H1 2026, including CoaChrom Diagnostica GmbH, illustrate an active pipeline, with newly acquired businesses already contributing significantly to earnings growth and smooth integration.

The decentralized model allows acquired companies to operate autonomously under AddLife’s umbrella, preserving entrepreneurial culture while benefiting from group capital, governance, and operational support. This approach has historically yielded strong post-acquisition performance in Nordic and European consolidator models. Investors will focus on the volume and scale of future deals, leverage impact given the stable 43 percent equity ratio, and the sustainability of acquired growth offsetting any organic demand softness. No full-year guidance was provided.

Stable Equity Ratio at 43% and Strong Return on Working Capital Above 60%

AddLife’s H1 2026 balance sheet metrics show financial stability. The equity ratio remained at 43 percent, unchanged from the prior year, indicating that acquisitions have not materially altered the group’s capital structure. This stability suggests acquisition funding has maintained financial resilience, although funding details and debt levels were not disclosed.

Return on working capital (P/WC) was 61 percent in H1 2026, slightly down from 62 percent the previous year, reflecting continued strong profitability relative to working capital deployed. The minor decline may result from integrating new acquisitions, which can temporarily affect capital efficiency. No further commentary on working capital changes was provided, and investors may seek clarification during the upcoming video conference.